Manufacturing

Specialized in liquid pharmaceuticals: Blow-Fill-Seal (BFS) technology and Nasal Spray.

Read More

Development

Your partner in bringing medical innovation to the market.

Read More

About Curida

Highly skilled Development and Manufacturing Organization with ambitions.

Read More

Contact Curida

Pharmaceutical Development or Manufacturing needs?

Contact Us

Operational Excellence in Pharmaceuticals since 1974

Curida is a Contract Development and Manufacturing Organization (CDMO) within the Pharmaceutical industry, based in Norway.

Curida has core competency in state-of-the-art manufacturing of Liquid Pharmaceuticals based on sterile unit-dose Blow-Fill-Seal (BFS) technology and Nasal Spray. The development expertise covers the full service for the development of nasal drug products, and experience on operational excellence is spanning more than 40 years. Curida has produced BFS products since 1989 and offers over three decades of know-how in this technology. Customers range from small start-ups and early stage Biotech companies to Big Pharma.

Curida is a part of an exciting and growing life science sector in Norway, and our vision is to be the National Centre for Industrialization of Medical Innovation. Curida is an active partner and member of Oslo Cancer Cluster.

Latest News

Curida blir råvareleverandør etter Sanivo Pharmas avvikling

Published: 14 Jun 2018

— Vi tar bestillinger nå og forventer å levere de første råvarene i august, sier daglig leder i Curida, Leif Rune Skymoen, til NFT. Torsdag 7. juni fikk legemiddelselskapet Curida innvilget utvidet tilvirkertillatelse av Statens legemiddelverk. Selskapet kan nå bestille råvarer, som senere […]

Read More
 

Governmental fund Investinor invests in Curida

Published: 23 Jan 2018

(Elverum, January 19th, 2018) Investinor, funded by the Norwegian government, invests 25 MNOK in the pharmaceutical development and manufacturing company Curida. The company has raised in total 75 MNOK. Canica and Klaveness Marine invested 25 MNOK each in December 2017. […]

Read More